Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it …

Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V., a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement …

(MENAFN- GlobeNewsWire - Nasdaq) Factors driving the market include rising disease prevalence, innovative therapies, and gene-based treatment breakthroughs. Key players like H Lundbeck and Pfizer are fueling research and development efforts worldwide. …

The FDA granted a breakthrough therapy designation to AMT-130 (uniQuire) for the treatment of Huntington disease. Previously, AMT-130 was also granted a regenerative medicine advanced therapy designation and orphan drug designation for this indication.1 …

~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulatory update and guidance on the Biologics License Application submission expected in the second …

For the brain to function normally, it needs a protein called BDNF. Low levels of this protein have been linked to depression, schizophrenia and Alzheimer's disease. A recent discovery by scientists could help lead to the development of future …

Funder: NHMRC; Aligning Science Across Parkinson’s; Medicine by Design (University of Toronto); Ontario Research Fund; seed fund from Monash University; The Florey acknowledges the strong support from the Victorian Government and in particular the funding …

HUNTINGTON — A new low-barrier overnight shelter that will provide basic needs and mental and medical services for unsheltered people in Huntington will be developed in the West End, Mayor Patrick Farrell announced from City Council Chambers on Tuesday. …

Ruth M. O'Regan Chair, Department of Medicine | University Of Rochester Medical Center Ruth M. O'Regan Chair, Department of Medicine | University Of Rochester Medical Center New research suggests that the adult brain can regenerate neurons that …

(MENAFN- PR Newswire) Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference SAN DIEGO, March 20, 2025 / …